October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments.


October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of September 2021. This is based on the website’s 200,902 pageviews for the month.

1. FDA Clears Fully Automated Cardiac Ultrasound Solution to Measure 2D and Doppler


October 6, 2021 – Biosense Webster announced the first cases using a radiofrequency balloon ablation catheter were completed in September at sites across Europe using the Biosense Webster Heliostar Balloon Ablation Catheter. In Europe, the Heliostar Balloon Catheter is indicated for use in catheter-based cardiac electrophysiology (EP) mapping of the atria and for cardiac ablation.


October 6, 2021 — Data presented during the late-breaking science session at the European Society of Cardiology (ESC) 2021 Congress showed the integration of perivascular fat attenuation in coronary vessels using computed tomography (CT) scans has the potential to significantly advance the prognostic utility of cardiac CT analysis in the investigation and management of coronary artery disease risk.



October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade reports that the rate of coronary computed tomography angiography (CCTA) exams by radiologists in hospital outpatient departments increased markedly from 2010 to 2019.[1] This suggests a bright future for the technology.


October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used  proprietary wearable cloth nanotechnology sensors and artificial intelligence (AI), received its third FDA 510(k) clearance and first software-only clearance as an end-to-end digital platform. This clearance enables Nanowear to implement standalone AI and deep learning algorithms that will inform remote diagnoses as software-as-a-medical sevice (SaMD). 

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke and transcatheter closure can avoid open heart surgery. 

Abbott said the Talisman system improves the efficiency and effectiveness of the PFO occlusion procedure compared to the previous generation PFO occluder.

October 4, 2021 – UltraSight, a digital health company developing artificial intelligence (AI) enabled cardiac imaging, announced a new collaboration with GE Healthcare to conduct a cardiac ultrasound study aboard the Axiom Rakia space mission. The company also announced the successful completion of preliminary design review (PDR) for its cardiac point-of-care-ultrasound (POCUS). 

October 4, 2021 — Here are links to all the late-breaking cardiology studies presented in Hot-Line sessions at the 2021 European Society of Cardiology (ESC) Congress. 

Drones Could Deliver Defibrillators to Cardiac Arrest Victims Faster Than Ambulances

Subscribe Now